Extract
The new short-course World Health Organization (WHO)-endorsed regimen for multidrug-resistant (MDR) tuberculosis (TB) resistant to rifampicin and isoniazid gives hope for patients and care-givers. However, there is still an unacceptable proportion of treatment failure and evidence of man-made acquired drug resistance of fluoroquinolones during programmatic treatment of MDR-TB [1]. The appropriate use of fluoroquinolones is crucial in MDR-TB treatment, perhaps even more so in the new WHO-endorsed short-course MDR-TB regimen. Current shortcomings with inappropriate use of fluoroquinolones, such as underdosing, need to be avoided in order to prevent failure of the new short-course regimen.
Abstract
Therapeutic drug monitoring of fluoroquinolones might prevent acquired XDR-TB http://ow.ly/jj6b309QXyZ
Footnotes
Conflict of interest: None declared.
- Received January 24, 2017.
- Accepted February 15, 2017.
- Copyright ©ERS 2017